{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:16:03Z","timestamp":1694632563250},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This commentary reviews the Buchegger et al. manuscript published in this issue of The Oncologist. The authors concur with Buchegger et al. and advocate greater use of radioimmunotherapy in advanced-stage low-grade follicular lymphoma.<\/jats:p>","DOI":"10.1634\/theoncologist.2008-0113","type":"journal-article","created":{"date-parts":[[2008,6,27]],"date-time":"2008-06-27T15:38:21Z","timestamp":1214581101000},"page":"655-656","source":"Crossref","is-referenced-by-count":3,"title":["Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma"],"prefix":"10.1093","volume":"13","author":[{"given":"John P.","family":"Plastaras","sequence":"first","affiliation":[{"name":"a Department of Radiation Oncology, Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Glatstein","sequence":"additional","affiliation":[{"name":"a Department of Radiation Oncology, Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"b Department of Medicine, Division of Hematology\/Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,6,1]]},"reference":[{"key":"2021122208462545300_R1","first-page":"563s","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"23","author":"Petersen","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208462545300_R2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: Prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122208462545300_R3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208462545300_R4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1634\/theoncologist.2008-0020","article-title":"Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma","volume":"13","author":"Buchegger","year":"2008","journal-title":"The Oncologist"},{"key":"2021122208462545300_R5","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2021122208462545300_R6","doi-asserted-by":"crossref","unstructured":"Hochster \u00a0HS, Weller \u00a0E, Gascoyne \u00a0RD et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts) \u00a02005; 106: 349.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"2021122208462545300_R7","doi-asserted-by":"crossref","unstructured":"Marcus \u00a0RE, Solal-Celigny \u00a0P, Imrie \u00a0K et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) \u00a02006; 108: 481.","DOI":"10.1182\/blood.V108.11.481.481"},{"key":"2021122208462545300_R8","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462545300_R9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208462545300_R10","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"2021122208462545300_R11","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"2021122208462545300_R12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V110.11.643.643","article-title":"90Y-ibritumomab tiuxetan (Zevalin\u00ae) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: First results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients","volume":"110","author":"Hagenbeek","year":"2007","journal-title":"Blood"},{"key":"2021122208462545300_R13","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462545300_R14","first-page":"1","article-title":"Market forces cited in lymphoma drugs' disuse","volume-title":"New York Times","author":"Berenson","year":"2007"},{"key":"2021122208462545300_R15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djk155","article-title":"Users fear that lymphoma drugs will disappear","volume":"99","author":"Garber","year":"2007","journal-title":"J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/655\/41832037\/oncolo_13_6_655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/655\/41832037\/oncolo_13_6_655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:26:00Z","timestamp":1640186760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/6\/655\/6396676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,1]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0113","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,6,1]]},"published":{"date-parts":[[2008,6,1]]}}}